Colleen Kusy
Stock Analyst at Baird
(1.67)
# 2,977
Out of 5,162 analysts
52
Total ratings
34.78%
Success rate
-0.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLYM Climb Bio | Maintains: Outperform | $9 → $12 | $7.03 | +70.70% | 2 | Mar 6, 2026 | |
| ARGX argenx SE | Maintains: Neutral | $858 → $867 | $700.45 | +23.78% | 2 | Feb 27, 2026 | |
| NUVL Nuvalent | Maintains: Outperform | $112 → $158 | $97.93 | +61.34% | 3 | Nov 18, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $14 → $34 | $34.00 | - | 1 | Nov 11, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $50 → $52 | $18.94 | +174.55% | 13 | Oct 31, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $17 → $24 | $8.76 | +173.97% | 5 | Oct 3, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $40 → $52 | $27.77 | +87.25% | 3 | Jun 16, 2025 | |
| AGEN Agenus | Maintains: Neutral | $4 → $6 | $3.10 | +93.55% | 4 | Jun 4, 2025 | |
| OCS Oculis Holding AG | Maintains: Outperform | $37 → $41 | $25.43 | +61.23% | 4 | Mar 13, 2025 | |
| CHRS Coherus Oncology | Maintains: Outperform | $4 → $6 | $1.63 | +268.10% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $65 | $39.89 | +62.95% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $27 → $25 | $11.90 | +110.08% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $255 → $210 | $7.85 | +2,575.16% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $3.96 | +758.59% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $4.15 | +5,442.17% | 1 | Nov 2, 2021 |
Climb Bio
Mar 6, 2026
Maintains: Outperform
Price Target: $9 → $12
Current: $7.03
Upside: +70.70%
argenx SE
Feb 27, 2026
Maintains: Neutral
Price Target: $858 → $867
Current: $700.45
Upside: +23.78%
Nuvalent
Nov 18, 2025
Maintains: Outperform
Price Target: $112 → $158
Current: $97.93
Upside: +61.34%
Cogent Biosciences
Nov 11, 2025
Maintains: Neutral
Price Target: $14 → $34
Current: $34.00
Upside: -
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Outperform
Price Target: $50 → $52
Current: $18.94
Upside: +174.55%
Ocular Therapeutix
Oct 3, 2025
Maintains: Outperform
Price Target: $17 → $24
Current: $8.76
Upside: +173.97%
Enliven Therapeutics
Jun 16, 2025
Maintains: Outperform
Price Target: $40 → $52
Current: $27.77
Upside: +87.25%
Agenus
Jun 4, 2025
Maintains: Neutral
Price Target: $4 → $6
Current: $3.10
Upside: +93.55%
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37 → $41
Current: $25.43
Upside: +61.23%
Coherus Oncology
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $1.63
Upside: +268.10%
Nov 13, 2024
Maintains: Outperform
Price Target: $50 → $65
Current: $39.89
Upside: +62.95%
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $11.90
Upside: +110.08%
Aug 5, 2022
Maintains: Outperform
Price Target: $255 → $210
Current: $7.85
Upside: +2,575.16%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $3.96
Upside: +758.59%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $4.15
Upside: +5,442.17%